secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0001654954-22-013566
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting
--------------------------------------------------------------------------------

- 18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.
- 6-minute walk distance improved by mean 13.1 m; BNP decreased by mean 133.3 pg/dL; NT-proBNP decreased by 239.4 pg/dL.
- KCCQ overall summary score improved 3.7 points; physical and clinical summary scores also improved.
- Oral formulation at 3-4 mg/day deemed safe and effective for chronic use, supporting Phase 3 testing.
- Data presented at HFSA Scientific Sessions 2022; investigators concluded oral levosimendan is well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/0001654954-22-013566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-013566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer